Bristol-Myers Squibb Co
Score: Negative (6)
11 days at current score.
Downgraded from Neutral on March 16th 2018
- This company ranked negatively compared to the Healthcare sector despite 2 positive IHS Markit Categories
- Perception of the company's creditworthiness is negative
- ETFs holding this stock have seen outflows over the last one-month
- Bearish sentiment is low
- Economic output in this company's sector is expanding
Short interest | Positive
Short interest is extremely low for BMY with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BMY.
ETF/Index ownership | Negative
ETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMY totaled $4.12 billion. Additionally, the rate of outflows appears to be accelerating.
PMI by IHS Markit | Positive
According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating.
Credit default swap | Negative
The current level displays a negative indicator. BMY credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness.
Please send all inquiries related to the report to firstname.lastname@example.org.
Charts and report PDFs will only be available for 30 days after publishing.
This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.